Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 15, 2010 | VP, Pharmacology & Biology | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 25,000 | |
| Dec 23, 2015 | Director, Chairman & CEO | Bona fide gift | Form 5 | 25,088 | -- | 96,692 | |
| Sep 30, 2015 | Director, Chairman & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 5 | 25,088 | $13.75 | 121,780 | |
| Jan 02, 2024 | Chief Accounting Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,252 | -- | 123,808 | |
| Sep 29, 2014 | Chief Financial Officer | Open market or private purchase of non-derivative or derivative security | Form 4 | 25,311 | $6.09 | 125,311 | |
| Sep 29, 2014 | Chief Financial Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 25,311 | $6.09 | 100,000 | |
| Dec 18, 2014 | Director, Chairman & CEO | Bona fide gift | Form 5 | 25,584 | -- | 83,499 | |
| Jun 27, 2019 | Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,964 | -- | 25,964 | |
| Feb 25, 2019 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 26,270 | $2.29 | 156,037 | |
| Feb 25, 2019 | Chief Medical Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 26,270 | $12.52 | 129,767 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.